强干扰素诱导病毒载体与低剂量 Nivolumab 加 Ipilimumab 的顺序组

StephenW

强干扰素诱导病毒载体与低剂量 Nivolumab 加 Ipilimumab 的顺序组合可提供慢性乙型肝炎病毒感染的功能性治疗：提出新模式的技术报告

Tibor Bakacs, Rifaat Safadi, László G. Puskás, Liliána Z. Fehér, Imre Kovesdi

发布时间：2022 年 3 月 1 日（见历史）

DOI：10.7759/cureus.22750

将本文引用为：Bakacs T、Safadi R、Puskás L G 等。 （2022 年 3 月 1 日）强干扰素诱导病毒载体与低剂量 Nivolumab 加 Ipilimumab 的顺序组合可以为慢性乙型肝炎病毒感染提供功能性治疗：提出一种新模式的技术报告。治愈 14（3）：e22750。 doi:10.7759/cureus.22750
抽象的

根据国际消除乙型肝炎病毒联盟 (ICE-HBV) 的建议，我们打算模拟 HBV 感染的自发消退，以实现慢性乙型肝炎病毒 (HBV) 感染的功能性治愈。为此，我们提出了先天性和适应性宿主免疫反应的顺序靶向。 HBV 复制和乙型肝炎表面抗原 (HbsAg) 产生的长期抑制将首先通过诱导强烈的先天免疫反应来实现。将实施经临床验证的病毒二重感染疗法 (SIT)，该疗法采用减毒、非溶解、双链 RNA (dsRNA) 传染性法氏囊病病毒 (IBDV)，可提供异常强的干扰素 (IFN) 反应。然后，通过免疫检查点抑制剂 (ICIs) 阻断细胞毒性 T 淋巴细胞相关抗原 4 (CTLA-4) 和程序性细胞死亡蛋白 1 (PD-1) 受体，可以恢复耗尽的 HBV 特异性 T 细胞功能。为了将任何毒性风险降至最低，将给予超说明书低剂量的纳武单抗（0.5 mg/kg）加易普利姆玛（0.3 mg/kg），其安全性和有效性已在 131 例未选择的 IV 期癌症中得到证实耐心。我们预测，这种联合疗法将在相对较短的治疗期内提供持续的非治疗病毒学和临床反应。

StephenW

Sequential Combination of a Strong Interferon Inducer Viral Vector With Low Doses of Nivolumab Plus Ipilimumab Could Provide Functional Cure in Chronic Hepatitis B Virus infections: Technical Report Proposing a New Modality

Tibor Bakacs , Rifaat Safadi , László G. Puskás , Liliána Z. Fehér, Imre Kovesdi

Published: March 01, 2022 (see history)

DOI: 10.7759/cureus.22750

Cite this article as: Bakacs T, Safadi R, Puskás L G, et al. (March 01, 2022) Sequential Combination of a Strong Interferon Inducer Viral Vector With Low Doses of Nivolumab Plus Ipilimumab Could Provide Functional Cure in Chronic Hepatitis B Virus infections: Technical Report Proposing a New Modality. Cureus 14(3): e22750. doi:10.7759/cureus.22750
Abstract

Based on the recommendation of the International Coalition to Eliminate hepatitis B virus (ICE-HBV), we intend to mimic the spontaneous resolution of HBV infection to achieve a functional cure of chronic hepatitis B virus (HBV) infection. To this end, we propose sequential targeting of the innate and adaptive host immune responses. Long-term suppression of HBV replication and hepatitis B surface antigen (HbsAg) production will be achieved first by inducing a strong innate immune response. The clinically validated viral superinfection therapy (SIT) will be administered, which employs an attenuated, non-lytic, double-stranded RNA (dsRNA) infectious bursal disease virus (IBDV) that provides an exceptionally strong interferon (IFN) response. Then, the exhausted HBV-specific T cell function will be restored by blocking the cytotoxic T lymphocyte-associated antigen-4 (CTLA‐4) and programmed cell death protein 1 (PD‐1) receptors with immune checkpoint inhibitors (ICIs). In order to minimize any risk of toxicity, off-label low doses of nivolumab (0.5 mg/kg) plus ipilimumab (0.3 mg/kg) will be administered, the safety and efficacy of which has already been demonstrated in 131 unselected stage IV cancer patients. We predict that this combination therapy will provide sustained off-treatment virological and clinical responses during a relatively short treatment period.

StephenW

https://www.cureus.com/articles/ ... sing-a-new-modality

newchinabok

hbsag很低，什么新药都好使

齐欢畅

纳武利尤单抗 (Nivolumab)

所有名称: 纳武单抗，欧狄沃，纳武利尤单抗，O药，Opdivo，Nivolumab，Opdyta
适应症: 纳武利尤单抗Nivolumab（商品名：欧狄沃Opdivo，之前国内有翻译纳武单抗，民间很多患者和家属称为O药）适用于转移性黑色素瘤、肾癌、经过治疗的晚期非小细胞肺癌、转移性肺癌。
品牌 : O药